表紙
市場調查報告書

醫藥品受託開發、製造的全球市場:2024年為止的預測

Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO)-Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 899261
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
Back to Top
醫藥品受託開發、製造的全球市場:2024年為止的預測 Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO)-Global Forecast to 2024
出版日期: 2019年07月29日內容資訊: 英文 187 Pages
簡介

醫藥品受託開發、製造市場預測將從2019年的900億美元以年複合成長率7.1%擴大,到2024年達到1,266億美元。高齡化,對醫藥品研究開發的增資,最新製造技術的投資等促進市場成長。

本報告提供全球醫藥品受託開發、製造市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 高級見解

第5章 市場概要

  • 簡介
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
    • 課題
    • 趨勢

第6章 各類服務市場

  • 簡介
  • 醫藥品製造服務
  • 藥物開發服務
  • 製造部製劑製造服務

第7章 各終端用戶市場

  • 簡介
  • 大型製藥公司
  • 小規模製藥公司
  • 學名藥廠商
  • 其他

第8章 各地區市場

  • 簡介
  • 歐洲
  • 北美
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 競爭環境

  • 概要
  • 市場排行榜
  • 競爭領導製圖
  • 競爭趨勢

第10章 企業簡介

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH 7263

"The global pharmaceutical contract development and manufacturing market is projected to grow at a CAGR of 7.1%."

The pharmaceutical contract development and manufacturing market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are major market challenges.

"The biologics manufacturing segment is expected to grow at the highest rate during the forecast period."

On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period. Growth in this segment is largely driven by the growing generics market and the impending patent cliff in the pharmaceuticals industry, which have propelled interest toward biologics.

"The big pharma end user segment is expected to account for the largest market share in 2019."

The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market. The emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets are factors contributing to the larger share of this segment.

"The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market."

Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and its highly skilled workforce are factors driving the growth of this regional segment.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1 (21%), Tier 2 (26%), and Tier 3 (53%)
  • By Designation: C-level (32%), Director-level (26%), and Others (42%)
  • By Region: North America (35%), Europe (30%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (10%)

The prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific (US), Catalent (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), and Siegfried Holding AG (Switzerland).

Research Coverage:

This report analyzes the market for various pharmaceutical contract development and manufacturing services and their adoption patterns. It aims at estimating the market size and future growth potential of the global pharmaceutical contract development and manufacturing market and its service, end user, and regional segments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global pharmaceutical contract development and manufacturing market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global pharmaceutical contract development and manufacturing market
  • Market Development: Comprehensive information on the lucrative emerging regions
  • Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global pharmaceutical contract development and manufacturing market
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies, revenue analysis, and services of leading players in the global pharmaceutical contract development and manufacturing market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primaries
      • 2.1.2.3 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 DATA TRIANGULATION APPROACH
  • 2.4 MARKET PLAYERS RANKING ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING: MARKET OVERVIEW
  • 4.2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.3 REGIONAL MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019-2024)
  • 4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2019 VS. 2024

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing demand for generics
      • 5.2.1.2 Increasing investments in pharmaceutical R&D
      • 5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Increasing demand for biological therapies
      • 5.2.2.2 Growing focus on specialty medicines
      • 5.2.2.3 Growth in the nuclear medicine sector
      • 5.2.2.4 Growing demand for cell and gene therapies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Introduction of serialization
      • 5.2.3.2 Changing trade policies between countries
    • 5.2.4 TRENDS
      • 5.2.4.1 Increasing CDMO manufacturing footprint in Asian countries
      • 5.2.4.2 CDMO industry consolidation
      • 5.2.4.3 Increasing outsourcing of clinical trials to emerging markets

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
      • 6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
    • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
      • 6.2.2.1 Parenteral/injectable manufacturing services
        • 6.2.2.1.1 Need for high levels of expertise and growing drug development activity are driving the demand for contract manufacturing
      • 6.2.2.2 Tablet manufacturing services
        • 6.2.2.2.1 Shifting manufacturing requirements and need to streamline production processes is driving market growth
      • 6.2.2.3 Capsule manufacturing services
        • 6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
      • 6.2.2.4 Oral liquid manufacturing services
        • 6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to look to outsourcing
      • 6.2.2.5 Other formulations

  • 6.3 DRUG DEVELOPMENT SERVICES
    • 6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
  • 6.4 BIOLOGICS MANUFACTURING SERVICES
    • 6.4.1 BIOLOGICS API MANUFACTURING SERVICES
      • 6.4.1.1 The market for biologics API manufacturing is still in the emergent phase
    • 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
      • 6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER

  • 7.1 INTRODUCTION
  • 7.2 BIG PHARMA
    • 7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPY FORMS TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
  • 7.3 SMALL & MID-SIZE PHARMA
    • 7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    • 7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
  • 7.5 OTHER END USERS

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION

  • 8.1 INTRODUCTION
  • 8.2 EUROPE
    • 8.2.1 ITALY
      • 8.2.1.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
    • 8.2.2 GERMANY
      • 8.2.2.1 High healthcare expenditure and increased pharmaceutical production to support market growth
    • 8.2.3 FRANCE
      • 8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
    • 8.2.4 UK
      • 8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
    • 8.2.5 SWITZERLAND
      • 8.2.5.1 Large volume of pharmaceutical production and growing scope for generics is expected to growth opportunities

    • 8.2.6 SPAIN
      • 8.2.6.1 Increase in biologics production to support market growth
    • 8.2.7 REST OF EUROPE
  • 8.3 NORTH AMERICA
    • 8.3.1 US
      • 8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market
    • 8.3.2 CANADA
      • 8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper market growth
  • 8.4 ASIA PACIFIC
    • 8.4.1 INDIA
      • 8.4.1.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
    • 8.4.2 CHINA
      • 8.4.2.1 Favorable government regulations are fueling market growth in China
    • 8.4.3 JAPAN
      • 8.4.3.1 Growing generics demand and push from the government will drive the demand for contract manufacturing of drugs
    • 8.4.4 REST OF ASIA PACIFIC
  • 8.5 LATIN AMERICA
    • 8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR THE CONTRACT MANUFACTURERS IN THE REGION

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 MARKET RANKING
    • 9.2.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY KEY PLAYERS, 2018
  • 9.3 COMPETITIVE LEADERSHIP MAPPING
    • 9.3.1 VISIONARY LEADERS
    • 9.3.2 INNOVATORS
    • 9.3.3 DYNAMIC DIFFERENTIATORS
    • 9.3.4 EMERGING COMPANIES
  • 9.4 COMPETITIVE SITUATION AND TRENDS
    • 9.4.1 PRODUCT LAUNCHES
    • 9.4.2 EXPANSIONS
    • 9.4.3 ACQUISITIONS
    • 9.4.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS

10 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 10.1 THERMO FISHER SCIENTIFIC INC.
  • 10.2 CATALENT, INC.
  • 10.3 LONZA GROUP LTD
  • 10.4 RECIPHARM AB
  • 10.5 VETTER PHARMA INTERNATIONAL GMBH
  • 10.6 FAMAR HEALTH CARE SERVICES
  • 10.7 ABBVIE INC.
  • 10.8 AENOVA GROUP
  • 10.9 CONSORT MEDICAL PLC
  • 10.10 ALMAC GROUP
  • 10.11 SIEGFRIED HOLDING AG
  • 10.12 EVONIK INDUSTRIES AG
  • 10.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 INSIGHTS OF INDUSTRY EXPERTS
  • 11.2 DISCUSSION GUIDE
  • 11.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.4 AVAILABLE CUSTOMIZATIONS
  • 11.5 RELATED REPORTS
  • 11.6 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 2: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 3: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 4: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 5: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 6: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 7: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 8: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 9: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 10: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 11: OTHER FORMULATION MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 12: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 13: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 14: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 15: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 16: BIOLOGICS FINISHED DOSAGE FORMULATIONS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 17: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 18: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMA, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 19: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MID-SIZE PHARMA, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 20: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 21: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 22: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23: EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 24: EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 25: EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 26: EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 27: EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 28: EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 29: ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 30: ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 31: ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 32: ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 33: ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 34: GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 35: GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 36: GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 37: GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 38: GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 39: FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 40: FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 41: FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 42: FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 43: FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 44: UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 45: UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 46: UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 47: UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 48: UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 49: SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 50: SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 51: SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 52: SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 53: SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 54: SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 55: SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 56: SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 57: SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 58: SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 59: ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 60: ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 61: ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 62: ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 63: ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 64: NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 65: NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 66: NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 67: NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 68: NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 69: NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 70: US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 71: US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 72: US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73: US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 74: US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 75: CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 76: CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 77: CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 78: CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 79: CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 80: ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 81: ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 82: ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 83: ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 84: ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 85: ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 86: INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 87: INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 88: INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 89: INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 90: INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 91: CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 92: CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 93: CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 94: CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 95: CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 96: JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 97: JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 98: JAPAN: FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 99: JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 100: JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 101: ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 102: ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 103: ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 104: ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 105: ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 106: LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 107: LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 108: LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 109: LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 110: LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 111: MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017-2024 (USD MILLION)
  • TABLE 112: MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 113: MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 114: MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 115: MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 116: PRODUCT LAUNCHES, 2016-2019
  • TABLE 117: EXPANSIONS, 2016-2019
  • TABLE 118: ACQUISITIONS, 2016-2019
  • TABLE 119: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2016-2019

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2019 VS. 2024 (USD BILLION)
  • FIGURE 7: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
  • FIGURE 8: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2019 VS. 2024 (USD BILLION)
  • FIGURE 9: GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • FIGURE 10: GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
  • FIGURE 11: INDIA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 12: ASIA PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD (2019-2024)
  • FIGURE 13: DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2019 & 2024
  • FIGURE 14: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
  • FIGURE 15: GROWTH OF THE GENERICS MARKET (2006 VS. 2016)
  • FIGURE 16: NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010-2017)
  • FIGURE 17: GLOBAL LIFE SCIENCE R&D SPENDING (2016-2018)
  • FIGURE 18: CDMO MERGER AND ACQUISITION VOLUME AND VALUE (2012-2016)
  • FIGURE 19: TOP CONSOLIDATORS (2012-2018)
  • FIGURE 20: PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE THE SERVICES MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: BIG PHARMA FORMED THE LARGEST END USER SEGMENT IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • FIGURE 22: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 23: EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
  • FIGURE 24: NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
  • FIGURE 25: ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
  • FIGURE 26: KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2016 TO JULY 2019
  • FIGURE 27: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANKING, BY KEY PLAYER, 2018
  • FIGURE 28: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: (GLOBAL) COMPETITIVE LEADERSHIP MAPPING (2018)
  • FIGURE 29: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 30: CATALENT, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 31: LONZA GROUP LTD: COMPANY SNAPSHOT (2018)
  • FIGURE 32: RECIPHARM AB: COMPANY SNAPSHOT (2018)
  • FIGURE 33: ABBVIE INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 34: CONSORT MEDICAL PLC: COMPANY SNAPSHOT (2018)
  • FIGURE 35: SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2018)
  • FIGURE 36: EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2018)
  • FIGURE 37: BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2018)
Back to Top